Independent register of U.S. FDA drug recalls · updated Oct 14, 2026
RxRecalls Get alerts

Class II drug recalls - moderate risk

Class II means the product may cause temporary or medically reversible harm, and serious harm is unlikely. It is by far the largest recall class - most potency, dissolution and labeling problems land here.

14,543 recalls, newest first.

Class II · Moderate risk

Magnesium Sulfate in Water for Injection

Correct Labeled Product Mispack: confirmed report involving a single unit of properly labeled Heparin in 0.45% Sodium Chloride for Injection (NDC 0409-7651-03, Lot 87903FW) that was found inside a case of Magnesium Sulfate in Water for Injection.

Terminated Labeling / mix-up Pfizer Inc. NDC 0409-6729-03 D-0015-2019
Class II · Moderate risk

Tesamorelin

Labeling: Incorrect or Missing Lot and/or Expiration Date; vial indicates a 1 year expiration date instead of a 6 month expiration date

Terminated Labeling / mix-up Tailor Made Compounding D-0223-2019
Class II · Moderate risk

Nystatin and Triamcinolone Acetonide Cream

Failed stability specifications - An out of specification result was observed for the test parameter : composition of Nystatin during stability testing.

Terminated Stability / shelf life Dr. Reddy's Laboratories, Inc. NDC 43598-431-44 D-0007-2019
Class II · Moderate risk

Clozapine Orally Disintegrating Tablets

Failed Disintegration Specifications: Out-of-specification disintegration test result obtained during routine stability testing.

Terminated Failed specification Teva Pharmaceuticals USA NDC 0093-5416-01 D-0001-2019
Class II · Moderate risk

Glipizide XL

CGMP Deviations; rejected product was used to manufacture final bulk lot

Terminated cGMP deviation Pfizer Inc. NDC 59762-0541-2 D-0010-2019
Class II · Moderate risk

Bumetanide Tablets

Failed impurities/ degradation specifications: Product is Out of Specification for an unspecified degradation product.

Terminated Impurity / degradation Upsher Smith Laboratories, Inc. NDC 0832-0542-11 D-0281-2019
Class II · Moderate risk

Bumetanide Tablets

Failed impurities/ degradation specifications: Product is Out of Specification for an unspecified degradation product.

Terminated Impurity / degradation Upsher Smith Laboratories, Inc. NDC 0832-0541-11 D-0280-2019
Class II · Moderate risk

Elelyso (taliglucerase alfa)

Lack of assurance of sterility -Reports of loose metal ferrule crimps on vials for injection. The entire cap either lifted or dislodged while attempting to flip off the orange color plastic button.

Terminated Sterility / contamination Pfizer Inc. NDC 0069-0106-01 D-0005-2019
Class II · Moderate risk

Lamotrigine Extended-Release Tablets

Failed Dissolution Specifications: Out of Specification for Dissolution test (Buffer Stage) at the 5-hour time point during stability testing.

Terminated Dissolution failure Torrent Pharma Inc. D-1204-2018

Recalls by year